Atomo Diagnostics Investor Relations Material
Latest events
Q2 2025
Atomo Diagnostics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Atomo Diagnostics Limited
Access all reports
Atomo Diagnostics Limited provides products in the areas of cancer, infectious diseases, and cardiovascular ailments. Its tests include Visca for diagnosing liver cancer and liver fibrosis/cirrhosis; MammaScreen for early breast cancer detection through measurements of plasma proteins (by testing blood); Chlamydia Screen for the screening or confirmation of Chlamydia trachomatis infections; HIV-1Virology Test System for the qualitative detection of antibodies to human immunodeficiency virus type 1 (HIV-1); and AtomoRapid Malaria Test that detects malaria infection in whole blood samples. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Key slides for Atomo Diagnostics Limited
H2 2024
Atomo Diagnostics Limited
H2 2024
Atomo Diagnostics Limited
Latest articles
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
AT1
Country
🇦🇺 Australia